BNP Paribas Arbitrage SA Reduces Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

BNP Paribas Arbitrage SA lessened its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 11.3% in the 1st quarter, Holdings Channel reports. The institutional investor owned 8,589 shares of the company’s stock after selling 1,092 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Pacira BioSciences were worth $602,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Penserra Capital Management LLC boosted its position in shares of Pacira BioSciences by 171.9% during the fourth quarter. Penserra Capital Management LLC now owns 995 shares of the company’s stock valued at $59,000 after buying an additional 629 shares during the period. Mascoma Wealth Management LLC purchased a new stake in shares of Pacira BioSciences in the first quarter valued at approximately $70,000. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Pacira BioSciences in the first quarter valued at approximately $65,000. Teacher Retirement System of Texas purchased a new stake in shares of Pacira BioSciences in the fourth quarter valued at approximately $219,000. Finally, Financial Counselors Inc. boosted its holdings in shares of Pacira BioSciences by 6.1% in the fourth quarter. Financial Counselors Inc. now owns 3,820 shares of the company’s stock valued at $229,000 after purchasing an additional 220 shares during the period.

Shares of PCRX stock opened at $59.18 on Friday. The business’s fifty day simple moving average is $63.90. The firm has a market capitalization of $2.61 billion, a P/E ratio of 17.83 and a beta of 1.10. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.83 and a current ratio of 3.10. Pacira BioSciences, Inc. has a 12-month low of $40.96 and a 12-month high of $80.00.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Monday, May 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.11). The business had revenue of $119.00 million for the quarter, compared to analyst estimates of $119.23 million. Pacira BioSciences had a return on equity of 11.09% and a net margin of 33.35%. The business’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. As a group, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current year.

In related news, VP Lauren Bullaro Riker sold 1,520 shares of the company’s stock in a transaction on Monday, March 15th. The stock was sold at an average price of $73.28, for a total value of $111,385.60. Following the transaction, the vice president now directly owns 14,701 shares of the company’s stock, valued at approximately $1,077,289.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Roy Winston sold 22,224 shares of the company’s stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $70.61, for a total value of $1,569,236.64. Following the completion of the transaction, the insider now directly owns 48,535 shares in the company, valued at $3,427,056.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,952 shares of company stock worth $6,917,472. Insiders own 6.20% of the company’s stock.

A number of analysts recently issued reports on PCRX shares. Northland Securities lowered their price target on Pacira BioSciences from $75.00 to $66.00 and set a “market perform” rating for the company in a report on Wednesday, May 5th. HC Wainwright boosted their price target on Pacira BioSciences from $70.00 to $86.00 and gave the company a “buy” rating in a report on Monday, March 1st. Zacks Investment Research upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and set a $65.00 target price for the company in a report on Tuesday. TheStreet lowered Pacira BioSciences from a “b” rating to a “c+” rating in a report on Thursday, April 8th. Finally, Berenberg Bank started coverage on Pacira BioSciences in a report on Friday, April 9th. They set a “buy” rating and a $93.00 target price for the company. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Pacira BioSciences has a consensus rating of “Buy” and a consensus target price of $77.54.

About Pacira BioSciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: Economic Reports

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.